The Experts below are selected from a list of 189900 Experts worldwide ranked by ideXlab platform
Robert J. Motzer - One of the best experts on this subject based on the ideXlab platform.
-
Development and Validation of a Prognostic Nomogram for Progression-Free Survival in Patients with Advanced Renal Cell Carcinoma Treated with Pazopanib
Oncology, 2015Co-Authors: Michael W. Kattan, Cora N. Sternberg, Faisal Mehmud, Kamal Bhatt, Lauren Mccann, Robert J. MotzerAbstract:Objective: To develop and validate a prognostic nomogram for predicting the probability of 12-month Progression-Free Survival (PFS) for patients receiving first-l
-
Quality of Life Predicts Progression-Free Survival in Patients With Metastatic Renal Cell Carcinoma Treated With Sunitinib Versus Interferon Alfa
Journal of oncology practice, 2009Co-Authors: David Cella, Joseph C. Cappelleri, Andrew G. Bushmakin, Claudie Charbonneau, Sindy T. Kim, Isan Chen, M. Dror Michaelson, Robert J. MotzerAbstract:In a randomized phase III trial, sunitinib was associated with significantly superior Progression-Free Survival when compared with interferon alfa as first-line therapy in patients with metastatic renal cell carcinoma. This article investigates whether baseline quality of life and demographic and clinical variables were predictive for Progression-Free Survival.
Feng Xie - One of the best experts on this subject based on the ideXlab platform.
-
Association between Progression-Free Survival and health-related quality of life in oncology: A systematic review and regression analysis.
Journal of Clinical Oncology, 2017Co-Authors: Bruno Kovic, Michael Brundage, Gordon H. Guyatt, Lehana Thabane, Xuejing Jin, Feng XieAbstract:6574Background: The goal of cancer care is to improve not only Survival duration but also health-related quality of life (HRQoL). Progression-Free Survival (PFS) has become an important surrogate o...
-
Association between Progression-Free Survival and health-related quality of life in oncology: a systematic review protocol
BMJ open, 2016Co-Authors: Bruno Kovic, Michael Brundage, Gordon H. Guyatt, Lehana Thabane, Neera Bhatnagar, Feng XieAbstract:Introduction There is an increasing number of new oncology drugs being studied, approved and put into clinical practice based on improvement in Progression-Free Survival, when no overall Survival benefits exist. In oncology, the association between Progression-Free Survival and health-related quality of life is currently unknown, despite its importance for patients with cancer, and the unverified assumption that longer Progression-Free Survival indicates improved health-related quality of life. Thus far, only 1 study has investigated this association, providing insufficient evidence and inconclusive results. The objective of this study protocol is to provide increased transparency in supporting a systematic summary of the evidence bearing on this association in oncology. Methods and analysis Using the OVID platform in MEDLINE, Embase and Cochrane databases, we will conduct a systematic review of randomised controlled human trials addressing oncology issues published starting in 2000. A team of reviewers will, in pairs, independently screen and abstract data using standardised, pilot-tested forms. We will employ numerical integration to calculate mean incremental area under the curve between treatment groups in studies for health-related quality of life, along with total related error estimates, and a 95% CI around incremental area. To describe the Progression-Free Survival to health-related quality of life association, we will construct a scatterplot for incremental health-related quality of life versus incremental Progression-Free Survival. To estimate the association, we will use a weighted simple regression approach, comparing mean incremental health-related quality of life with either median incremental Progression-Free Survival time or the Progression-Free Survival HR, in the absence of overall Survival benefit. Discussion Identifying direction and magnitude of association between Progression-Free Survival and health-related quality of life is critically important in interpreting results of oncology trials. Systematic evidence produced from our study will contribute to improvement of patient care and practice of evidence-based medicine in oncology.
Michael Brundage - One of the best experts on this subject based on the ideXlab platform.
-
Imaging Progression-Free Survival: How much does it matter to patients?
Journal of Clinical Oncology, 2018Co-Authors: Jennifer O’donnell, Andrew Robinson, Christopher M. Booth, Rachel Koven, Elizabeth A. Eisenhauer, Michael BrundageAbstract:99Background: Progression-Free Survival (PFS) is often used as a clinical trials outcome for evaluating new therapies for solid tumors. While PFS is a validated surrogate for overall Survival (OS) ...
-
Association between Progression-Free Survival and health-related quality of life in oncology: A systematic review and regression analysis.
Journal of Clinical Oncology, 2017Co-Authors: Bruno Kovic, Michael Brundage, Gordon H. Guyatt, Lehana Thabane, Xuejing Jin, Feng XieAbstract:6574Background: The goal of cancer care is to improve not only Survival duration but also health-related quality of life (HRQoL). Progression-Free Survival (PFS) has become an important surrogate o...
-
Association between Progression-Free Survival and health-related quality of life in oncology: a systematic review protocol
BMJ open, 2016Co-Authors: Bruno Kovic, Michael Brundage, Gordon H. Guyatt, Lehana Thabane, Neera Bhatnagar, Feng XieAbstract:Introduction There is an increasing number of new oncology drugs being studied, approved and put into clinical practice based on improvement in Progression-Free Survival, when no overall Survival benefits exist. In oncology, the association between Progression-Free Survival and health-related quality of life is currently unknown, despite its importance for patients with cancer, and the unverified assumption that longer Progression-Free Survival indicates improved health-related quality of life. Thus far, only 1 study has investigated this association, providing insufficient evidence and inconclusive results. The objective of this study protocol is to provide increased transparency in supporting a systematic summary of the evidence bearing on this association in oncology. Methods and analysis Using the OVID platform in MEDLINE, Embase and Cochrane databases, we will conduct a systematic review of randomised controlled human trials addressing oncology issues published starting in 2000. A team of reviewers will, in pairs, independently screen and abstract data using standardised, pilot-tested forms. We will employ numerical integration to calculate mean incremental area under the curve between treatment groups in studies for health-related quality of life, along with total related error estimates, and a 95% CI around incremental area. To describe the Progression-Free Survival to health-related quality of life association, we will construct a scatterplot for incremental health-related quality of life versus incremental Progression-Free Survival. To estimate the association, we will use a weighted simple regression approach, comparing mean incremental health-related quality of life with either median incremental Progression-Free Survival time or the Progression-Free Survival HR, in the absence of overall Survival benefit. Discussion Identifying direction and magnitude of association between Progression-Free Survival and health-related quality of life is critically important in interpreting results of oncology trials. Systematic evidence produced from our study will contribute to improvement of patient care and practice of evidence-based medicine in oncology.
Bruno Kovic - One of the best experts on this subject based on the ideXlab platform.
-
Association between Progression-Free Survival and health-related quality of life in oncology: A systematic review and regression analysis.
Journal of Clinical Oncology, 2017Co-Authors: Bruno Kovic, Michael Brundage, Gordon H. Guyatt, Lehana Thabane, Xuejing Jin, Feng XieAbstract:6574Background: The goal of cancer care is to improve not only Survival duration but also health-related quality of life (HRQoL). Progression-Free Survival (PFS) has become an important surrogate o...
-
Association between Progression-Free Survival and health-related quality of life in oncology: a systematic review protocol
BMJ open, 2016Co-Authors: Bruno Kovic, Michael Brundage, Gordon H. Guyatt, Lehana Thabane, Neera Bhatnagar, Feng XieAbstract:Introduction There is an increasing number of new oncology drugs being studied, approved and put into clinical practice based on improvement in Progression-Free Survival, when no overall Survival benefits exist. In oncology, the association between Progression-Free Survival and health-related quality of life is currently unknown, despite its importance for patients with cancer, and the unverified assumption that longer Progression-Free Survival indicates improved health-related quality of life. Thus far, only 1 study has investigated this association, providing insufficient evidence and inconclusive results. The objective of this study protocol is to provide increased transparency in supporting a systematic summary of the evidence bearing on this association in oncology. Methods and analysis Using the OVID platform in MEDLINE, Embase and Cochrane databases, we will conduct a systematic review of randomised controlled human trials addressing oncology issues published starting in 2000. A team of reviewers will, in pairs, independently screen and abstract data using standardised, pilot-tested forms. We will employ numerical integration to calculate mean incremental area under the curve between treatment groups in studies for health-related quality of life, along with total related error estimates, and a 95% CI around incremental area. To describe the Progression-Free Survival to health-related quality of life association, we will construct a scatterplot for incremental health-related quality of life versus incremental Progression-Free Survival. To estimate the association, we will use a weighted simple regression approach, comparing mean incremental health-related quality of life with either median incremental Progression-Free Survival time or the Progression-Free Survival HR, in the absence of overall Survival benefit. Discussion Identifying direction and magnitude of association between Progression-Free Survival and health-related quality of life is critically important in interpreting results of oncology trials. Systematic evidence produced from our study will contribute to improvement of patient care and practice of evidence-based medicine in oncology.
David N Louis - One of the best experts on this subject based on the ideXlab platform.
-
gain of chromosome arm 1q in atypical meningioma correlates with shorter Progression Free Survival
Neuropathology and Applied Neurobiology, 2012Co-Authors: M Jansen, Gayatry Mohapatra, Rebecca A Betensky, C Keohane, David N LouisAbstract:M. Jansen, G. Mohapatra, R. A. Betensky, C. Keohane and D. N. Louis (2012) Neuropathology and Applied Neurobiology38, 213–219 Gain of chromosome arm 1q in atypical meningioma correlates with shorter Progression-Free Survival Aims: Atypical (World Health Organization grade II) meningiomas have moderately high recurrence rates; even for completely resected tumours, approximately one-third will recur. Post-operative radiotherapy may aid local control and improve Survival, but carries the risk of side effects. More accurate prediction of recurrence risk is therefore needed for patients with atypical meningioma. Previously, we used high-resolution array comparative genomic hybridization to identify genetic variations in 47 primary atypical meningiomas and found that approximately 60% of tumours show gain of 1q at 1q25.1 and 1q25.3 to 1q32.1 and that 1q gain appeared to correlate with shorter Progression-Free Survival. This study aimed to validate and extend these findings in an independent sample. Methods: Eighty-six completely resected atypical meningiomas (with 25 recurrences) from two neurosurgical centres in Ireland were identified and clinical follow-up was obtained. Utilizing a dual-colour interphase fluorescence in situ hybridization assay, 1q gain was assessed using Bacterial Artificial Chromosome probes directed against 1q25.1 and 1q32.1. Results: The results confirm the high prevalence of 1q gain at these loci in atypical meningiomas. We further show that gain at 1q32.1 and age each correlate with Progression-Free Survival in patients who have undergone complete surgical resection of atypical meningiomas. Conclusions: These independent findings suggest that assessment of 1q copy number status can add clinically useful information for the management of patients with atypical meningiomas.
-
Gain of chromosome arm 1q in atypical meningioma correlates with shorter Progression‐Free Survival
Neuropathology and applied neurobiology, 2012Co-Authors: M Jansen, Gayatry Mohapatra, Rebecca A Betensky, C Keohane, David N LouisAbstract:M. Jansen, G. Mohapatra, R. A. Betensky, C. Keohane and D. N. Louis (2012) Neuropathology and Applied Neurobiology38, 213–219 Gain of chromosome arm 1q in atypical meningioma correlates with shorter Progression-Free Survival Aims: Atypical (World Health Organization grade II) meningiomas have moderately high recurrence rates; even for completely resected tumours, approximately one-third will recur. Post-operative radiotherapy may aid local control and improve Survival, but carries the risk of side effects. More accurate prediction of recurrence risk is therefore needed for patients with atypical meningioma. Previously, we used high-resolution array comparative genomic hybridization to identify genetic variations in 47 primary atypical meningiomas and found that approximately 60% of tumours show gain of 1q at 1q25.1 and 1q25.3 to 1q32.1 and that 1q gain appeared to correlate with shorter Progression-Free Survival. This study aimed to validate and extend these findings in an independent sample. Methods: Eighty-six completely resected atypical meningiomas (with 25 recurrences) from two neurosurgical centres in Ireland were identified and clinical follow-up was obtained. Utilizing a dual-colour interphase fluorescence in situ hybridization assay, 1q gain was assessed using Bacterial Artificial Chromosome probes directed against 1q25.1 and 1q32.1. Results: The results confirm the high prevalence of 1q gain at these loci in atypical meningiomas. We further show that gain at 1q32.1 and age each correlate with Progression-Free Survival in patients who have undergone complete surgical resection of atypical meningiomas. Conclusions: These independent findings suggest that assessment of 1q copy number status can add clinically useful information for the management of patients with atypical meningiomas.
